Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease characterized by intense itching, eczematous lesions, and significant quality-of-life impact. Globally, AD continues to place a high medical and economic burden, with 129 million people affected in 2021 and 16 million new cases reported that year, according to the Global Burden of Disease Study. Prevalence is highest in children, though many patients experience persistent symptoms into adulthood, and women show slightly higher rates overall. Geographic disparities highlight genetic and environmental influences. The atopic dermatitis pipeline analysis by Expert Market Research tracks the emerging therapies reshaping treatment landscapes.
Major companies involved in the atopic dermatitis pipeline analysis include Akeso, Bristol Myers Squibb, Qilu Pharmaceutical Co., Ltd., Keymed Biosciences Co. Ltd, and others.
Leading drugs currently in the pipeline include LNK01001, QL2108 injection and others.
The atopic dermatitis pipeline is expanding rapidly, driven by increasing prevalence, unmet therapeutic needs, and innovative mechanisms of action, positioning emerging biologics and small molecules to transform treatment landscapes and fuel sustained market growth globally.
The atopic dermatitis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into atopic dermatitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for atopic dermatitis. The atopic dermatitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The atopic dermatitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with atopic dermatitis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to atopic dermatitis.
Read more about this report - Request a Free Sample
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by intense itching, recurrent flares, and dry, inflamed skin. First-line management includes moisturizers, topical corticosteroids, and calcineurin inhibitors, while moderate-to-severe cases often require systemic agents such as biologics that target key inflammatory pathways. For instance, in December 2024, the FDA approved Nemluvio (nemolizumab), an IL-31 receptor–blocking monoclonal antibody, offering a major advancement for patients whose symptoms persist despite standard therapies. This approval marks a significant step forward in expanding effective, targeted treatment options for AD.
Atopic dermatitis (AD) remains a widespread chronic inflammatory skin condition with a substantial global burden. In 2021, an estimated 129 million people were living with AD worldwide, according to the Global Burden of Disease Study. That same year, approximately 16 million new cases emerged, reflecting its persistent incidence across both developed and developing regions. AD affects all age groups but is most common in children, with many continuing to experience symptoms into adulthood. Women often report slightly higher prevalence, and geographic variation suggests environmental and genetic factors significantly influence disease distribution globally.
This section of the report covers the analysis of atopic dermatitis drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The atopic dermatitis pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, Phase II dominates the landscape, accounting for 38% of total clinical trials and reflecting strong mid-stage innovation. Phase III closely follows at 36%, underscoring robust late-stage progression. Phase I represents 16% while Phase IV comprises 8.43%, reflecting an evolving atopic dermatitis therapeutic pipeline.
The drug molecule categories covered under the atopic dermatitis pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers, and gene therapies. The atopic dermatitis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for atopic dermatitis. In September 2024, the U.S. FDA approved EBGLYSS (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis in adults and adolescents (≥12 years), marking a major advancement in targeted biologic therapy. Developed by Eli Lilly, EBGLYSS selectively blocks IL-13, a central cytokine in atopic dermatitis pathophysiology, offering durable skin clearance and improved itch relief for patients inadequately controlled by topical treatments. The approval significantly strengthens the competitive pipeline landscape by diversifying the IL-13–focused class, accelerating innovation in mid- and late-stage immunomodulators, and stimulating both lifecycle management and next-generation biologic development across global markets.
The EMR report for the atopic dermatitis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed atopic dermatitis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in atopic dermatitis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for atopic dermatitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of atopic dermatitis drug candidates.
GR1802 Injection is a novel biological agent designed to modulate key inflammatory pathways implicated in atopic dermatitis, primarily by targeting cytokine signaling to reduce chronic skin inflammation and barrier dysfunction. Its mechanism aims to deliver rapid symptom relief and durable disease control, reflecting the growing importance of biologics in immunodermatology. Developed by Genrix (Shanghai) Biopharmaceutical, a company advancing innovative immune-modulating therapies, GR1802 strengthens the biological drug class by offering targeted, highly specific intervention with potential for improved safety and long-term efficacy.
TAVO101 is an emerging therapeutic candidate engineered to inhibit core inflammatory mediators driving atopic dermatitis, enabling a focused reduction in pruritus, erythema, and flare frequency. Its targeted mechanism aligns with next-generation small-molecule innovation, offering potentially convenient oral administration with meaningful efficacy. Developed by Tavotek Biotherapeutics, a company known for antibody and multi-domain therapeutic platforms, TAVO101 exemplifies the rising importance of small-molecule immunomodulators that complement biologics, expand patient accessibility, and provide alternative treatment options for those requiring flexible, systemic disease control.
AK120 is a monoclonal antibody targeting the IL-4 and IL-13 signaling pathways central to atopic dermatitis pathophysiology, aiming to suppress Th2-driven inflammation and restore skin homeostasis. As part of the rapidly growing biologic drug class, AK120 reflects the strong clinical value of pathway-specific intervention and potential for robust symptom improvement. It is developed by Akeso, a biotechnology company recognized for its bispecific antibody platforms and immunology-focused pipeline. AK120 strengthens the competitive landscape by offering targeted efficacy, long-term disease control, and innovation in biologically driven therapy.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Atopic Dermatitis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for atopic dermatitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into atopic dermatitis collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share